Addex Therapeutics (APE1) Stock Statistics & Valuation Metrics
Total Valuation
Addex Therapeutics has a market cap or net worth of EUR 3.14M. The enterprise value is EUR 4.97M.
- Market Cap
- EUR 3.14M
- Enterprise Value
- EUR 4.97M
Share Statistics
Addex Therapeutics has 2,597,121 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,597,121
- Owned by Insiders
- 67.23%
- Owned by Institutions
- 0.05%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -54.40%.
- Return on Equity (ROE)
- -1.41
- Return on Assets (ROA)
- -1.06
- Return on Invested Capital (ROIC)
- -54.40%
- Return on Capital Employed (ROCE)
- -0.54
- Revenue Per Employee
- 9,990.667
- Profits Per Employee
- -2.24M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is -0.48. Addex Therapeutics’s PEG ratio is -0.02.
- PE Ratio
- -0.48
- PS Ratio
- 45.57
- PB Ratio
- 2.07
- Price to FCF
- -1.21
- Price to Operating Cash Flow
- -1.65
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 29.97K and earned -6.73M in profits. Earnings per share was -6.88.
- Revenue
- 29.97K
- Gross Profit
- 29.97K
- Operating Income
- -2.81M
- Pretax Income
- -6.84M
- Net Income
- -6.73M
- EBITDA
- -6.83M
- Earnings Per Share (EPS)
- -6.88
Cash Flow
In the last 12 months, operating cash flow was -2.38M and capital expenditures -4, giving a free cash flow of -2.38M billion.
- Operating Cash Flow
- -2.38M
- Free Cash Flow
- -2.38M
- Free Cash Flow per Share
- -1.64
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -82.96%
- Earnings Yield
- -174.25%
Stock Price Statistics
- Beta
- 1.02
- 52-Week Price Change
- -65.68%
- 50-Day Moving Average
- 3.14
- 200-Day Moving Average
- 4.83
- Relative Strength Index (RSI)
- 42.36
- Average Volume (3m)
- ―
Important Dates
Addex Therapeutics upcoming earnings date is Nov 09, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Sep 28, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 0.73%
- Current Ratio
- 1.40
- Quick Ratio
- 1.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- -1162.58
Taxes
In the past 12 months, Addex Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.92.
- EV to Sales
- 34.65
- EV to EBITDA
- -0.64
- EV to Free Cash Flow
- -0.92
- EV to Operating Cash Flow
- -0.92
Balance Sheet
Addex Therapeutics has EUR 767.33K in cash and marketable securities with EUR 77.50K in debt, giving a net cash position of EUR 689.83K billion.
- Cash & Marketable Securities
- EUR 767.33K
- Total Debt
- EUR 77.50K
- Net Cash
- EUR 689.83K
- Net Cash Per Share
- EUR 0.27
- Tangible Book Value Per Share
- EUR 1.31
Margins
Gross margin is 41.19%, with operating margin of -4115.07%, and net profit margin of -10874.58%.
- Gross Margin
- 41.19%
- Operating Margin
- -4115.07%
- Pretax Margin
- -10867.08%
- Net Profit Margin
- -10874.58%
- EBITDA Margin
- -5446.68%
- EBIT Margin
- -5508.56%
